These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20132857)

  • 1. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment.
    Berthiaume JM; Wallace KB
    Cardiovasc Toxicol; 2007; 7(3):178-91. PubMed ID: 17901561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts.
    Sorokina N; O'Donnell JM; McKinney RD; Pound KM; Woldegiorgis G; LaNoue KF; Ballal K; Taegtmeyer H; Buttrick PM; Lewandowski ED
    Circulation; 2007 Apr; 115(15):2033-41. PubMed ID: 17404155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
    Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis.
    Wallace KB
    Cardiovasc Toxicol; 2007; 7(2):101-7. PubMed ID: 17652813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling the metabolic rewiring in the context of doxorubicin-induced cardiotoxicity: Fuel preference changes from fatty acids to glucose oxidation.
    Guerra G; Russo M; Priolo R; Riganti C; Reano S; Filigheddu N; Hirsch E; Ghigo A
    Vascul Pharmacol; 2024 Jun; 155():107324. PubMed ID: 38985581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
    Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
    Shaker O; Sourour DA
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart.
    Montaigne D; Marechal X; Baccouch R; Modine T; Preau S; Zannis K; Marchetti P; Lancel S; Neviere R
    Toxicol Appl Pharmacol; 2010 May; 244(3):300-7. PubMed ID: 20096298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
    Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
    Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats--relevance for mitochondrial dysfunction.
    Oliveira PJ; Wallace KB
    Toxicology; 2006 Mar; 220(2-3):160-8. PubMed ID: 16427179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced effects of L-carnitine on glucose and fatty acid metabolism in myocytes isolated from diabetic rats.
    Abdel-aleem S; Karim AM; Zarouk WA; Taylor DA; el-Awady MK; Lowe JE
    Horm Metab Res; 1997 Sep; 29(9):430-5. PubMed ID: 9370110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
    Oliveira PJ; Bjork JA; Santos MS; Leino RL; Froberg MK; Moreno AJ; Wallace KB
    Toxicol Appl Pharmacol; 2004 Oct; 200(2):159-68. PubMed ID: 15476868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
    Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure.
    Lou H; Danelisen I; Singal PK
    J Mol Cell Cardiol; 2004 May; 36(5):683-90. PubMed ID: 15135663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.